Failure in pivotal PhIII brain cancer trial drags Israel's VBL Therapeutics down
VBL Therapeutics $VBLT is in crisis mode this morning after it announced that its lead drug flunked a Phase III study in brain cancer.
The trial, which compared a combo of VB-111 and Roche’s Avastin (bevacizumab) against Avastin alone among patients with recurrent glioblastoma, failed the primary endpoint of overall survival. That’s dispiriting news for the Tel Aviv-based micro-cap, which has touted VB-111’s orphan drug and fast track designations every chance it gets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.